$0.670
-0.302 (-45.12%)Zum Schluss
- High
- 1.180
- Open
- 1.180
- VWAP
- 0.77
- Vol
- 2.78M
- Mkt Cap
- 1.43M
- Low
- 0.450
- Amount
- 2.13M
- EV/EBITDA, TTM
- 0.00
Virpax Pharmaceuticals, Inc. is a preclinical-stage pharmaceutical company. The Company is focused on developing novel and drug delivery systems. Its drug-delivery systems and drug-releasing technologies being developed are focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system (CNS) disorders to enhance patients’ quality of life. Its portfolio consists of multiple preclinical stage product candidates: Epoladerm, Probudur, Envelta, PES200, AnQlar and NobrXiol. Probudur is a drug product candidate based on a liposomal delivery system utilizing large multi-vesicular vesicles (LMVVs) encapsulating a high dose of the local anesthetic bupivacaine. PES200 enables the delivery of a metabolically labile peptide drug (Enkephalin) into the brain for post-traumatic stress disorder. NobrXiol is being developed by Nanomerics as an investigational formulation delivered via the nasal route to enhance Cannabidiol transport to the brain.
Bewertungskennzahlen
Event-Zeitleiste
News
2.003-20Business InsiderVirpax Pharmaceuticals Inc trading halted, news pending
9.503-20BenzingaWhy Five Below Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
7.503-20BenzingaUS Stocks Likely To Open Higher As Fed Says Tariff Induced Inflation Will Be 'Transitory:' Any Pullback In Equities 'Offers An Opportunity,' Says Expert
9.503-19BenzingaWhy StoneCo Shares Are Trading Higher By 8%; Here Are 20 Stocks Moving Premarket
2.003-19SeekingAlphaVirpax Pharmaceuticals to conduct reverse stock split
VRPX FAQ — answered by Alphio AI
Virpax Pharmaceuticals, Inc. is a preclinical-stage pharmaceutical company. The Company is focused on developing novel and drug delivery systems. Its drug-delivery systems and drug-releasing technologies being developed are focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system (CNS) disorders to enhance patients’ quality of life. Its portfolio consists of multiple preclinical stage product candidates: Epoladerm, Probudur, Envelta, PES200, AnQlar and NobrXiol. Probudur is a drug product candidate based on a liposomal delivery system utilizing large multi-vesicular vesicles (LMVVs) encapsulating a high dose of the local anesthetic bupivacaine. PES200 enables the delivery of a metabolically labile peptide drug (Enkephalin) into the brain for post-traumatic stress disorder. NobrXiol is being developed by Nanomerics as an investigational formulation delivered via the nasal route to enhance Cannabidiol transport to the brain. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.